Resumo
Definição
História e exame físico
Principais fatores diagnósticos
- presença de fatores de risco
- movimento de um lado do corpo ou uma parte específica do corpo
- sensação ou experiência premonitória (medo, sensação epigástrica, déjà vu, jamais vu)
- automatismos (puxar roupas, estalar os lábios)
- afasia temporária
- olhar fixo e não ter consciência dos arredores
Outros fatores diagnósticos
- deficit neurológico focal pós-ictal (paralisia de Todd, afasia)
- deficit neurológico focal persistente
- dificuldades de memória
- estigmas de síndromes neurocutâneas
Fatores de risco
- convulsão febril
- lesão cerebral traumática
- infecção do sistema nervoso central (SNC)
- acidente vascular cerebral (AVC)
- tumor cerebral
- deficiência intelectual e/ou paralisia cerebral
- demência
- história familiar de convulsões
- malformações vasculares intracranianas
- malformações do desenvolvimento cortical (MDC)
- sexo masculino
Investigações diagnósticas
Primeiras investigações a serem solicitadas
- glicemia
- Hemograma completo
- painel de eletrólitos
- análise toxicológica
- punção lombar e análise do líquido cefalorraquidiano
- tomografia computadorizada (TC) do crânio
- ressonância nuclear magnética (RNM) cranioencefálica
- eletroencefalograma (EEG)
Investigações a serem consideradas
- monitoramento de longa duração por vídeo/eletroencefalograma (EEG)
- tomografia por emissão de pósitrons (PET)
- tomografia computadorizada por emissão de fóton único (SPECT)
- RNM funcional
- exame de magnetoencefalografia (MEG)
- exame neuropsicológico
- teste de Wada
Novos exames
- RNM de 7T
Algoritmo de tratamento
convulsões agudas repetitivas: na comunidade
convulsões agudas repetitivas: no hospital
adultos <60 anos de idade: não gestantes ou sem risco de gestação
adultos ≥60 anos de idade
mulheres em idade fértil
gestante
crianças
Colaboradores
Autores
Ramses Ribot, MD
Assistant Professor of Clinical Neurology
Department of Neurology, Epilepsy Division
University of Miami, Miller School of Medicine
Miami
FL
Declarações
RR declares that he has no competing interests.
Andres M. Kanner, MD, FANA, FAES, FAAN
Professor of Clinical Neurology
Director, Comprehensive Epilepsy Center and Head, Section of Epilepsy
Department of Neurology
University of Miami, Miller School of Medicine
Miami
FL
Declarações
AMK has received honoraria from Eisai Laboratories for lectures given at international scientific meetings, and from the Epilepsy Foundation of America for being Co-Editor in Chief of Epilepsy.com. AMK is an author of a number of references cited in this topic.
Agradecimentos
Dr Ramses Ribot and Dr Andres M. Kanner would like to gratefully acknowledge Dr Vikram R. Rao, Dr John D. Hixson, and Dr Jeffrey Cohen, previous contributors to this topic.
Declarações
VRR served as a paid consultant for Neuropace, Inc., manufacturer of the Responsive Neurostimulation (RNS) System. JDH has received research funding and consultancy funds from UCB, Inc. JC declares that he has no competing interests.
Revisores
Edward Bromfield, MD
Chief
Epilepsy Division
Brigham and Women's Hospital
Associate Professor of Neurology
Harvard Medical School
Boston
MA
Declarações
At the time of review, EB declared that between 2004 and 2009, he received speaking honoraria from UCB Pharma, Novartis, Abbott Laboratories, GlaxoSmithKline, and Pfizer. He received consulting fees from UCB Pharma, Genzyme, and Spherics, and research funding from UCB Pharma. Unfortunately, we have since been made aware that EB is deceased.
Angus A. Wilfong, MD
Associate Professor
Pediatrics and Neurology
Baylor College of Medicine
Medical Director
Comprehensive Epilepsy Program
Texas Children's Hospital
Houston
TX
Declarações
AAW declares that he has no competing interests.
Cigdem I. Akman, MD
Assistant Professor
Division of Pediatric Neurology
Columbia University College of Physicians and Surgeons
New York
NY
Declarações
Not disclosed.
Pasquale Striano, MD, PhD
Consultant Neurologist
Muscular and Neurodegenerative Diseases Unit
"G Gaslini" Institute
Genova
Epilepsy Centre
Federico II University
Napoli
Italy
Divulgaciones
PS declares that he has no competing interests.
Agradecimiento de los revisores por pares
Los temas de BMJ Best Practice se actualizan de forma continua de acuerdo con los desarrollos en la evidencia y en las guías. Los revisores por pares listados aquí han revisado el contenido al menos una vez durante la historia del tema.
Divulgaciones
Las afiliaciones y divulgaciones de los revisores por pares se refieren al momento de la revisión.
Referencias
Artículos principales
Fisher RS, Cross JH, French JA, et al. Operational classification of seizure types by the International League Against Epilepsy: position paper of the ILAE Commission for Classification and Terminology. Epilepsia. 2017 Apr;58(4):522-30.Texto completo Resumen
Scheffer IE, Berkovic S, Capovilla G, et al. ILAE classification of the epilepsies: position paper of the ILAE Commission for Classification and Terminology. Epilepsia. 2017 Apr;58(4):512-21.Texto completo Resumen
Leone MA, Giussani G, Nevitt SJ, et al. Immediate antiepileptic drug treatment, versus placebo, deferred, or no treatment for first unprovoked seizure. Cochrane Database Syst Rev. 2021 May 4;(5):CD007144.Texto completo Resumen
Kanner AM, Ashman E, Gloss D, et al. Practice guideline update summary: efficacy and tolerability of the new antiepileptic drugs I: treatment of new-onset epilepsy. Report of the American Epilepsy Society and the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology. Epilepsy Curr. 2018 Jul-Aug;18(4):260-8.Texto completo Resumen
Kanner AM, Ashman E, Gloss D, et al. Practice guideline update summary: efficacy and tolerability of the new antiepileptic drugs II: treatment-resistant epilepsy. Report of the American Epilepsy Society and the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology. Epilepsy Curr. 2018 Jul-Aug;18(4):269-78.Texto completo Resumen
Royal College of Obstetricians and Gynaecologists. Epilepsy in pregnancy (Green-top Guideline No.68). Jun 2016 (updated May 2018) [internet publication].Texto completo
Nevitt SJ, Sudell M, Weston J, et al. Antiepileptic drug monotherapy for epilepsy: a network meta-analysis of individual participant data. Cochrane Database Syst Rev. 2017 Dec 15;(12):CD011412.Texto completo Resumen
Boon P, De Cock E, Mertens A, et al. Neurostimulation for drug-resistant epilepsy: a systematic review of clinical evidence for efficacy, safety, contraindications and predictors for response. Curr Opin Neurol. 2018 Apr;31(2):198-210. Resumen
Artículos de referencia
Una lista completa de las fuentes a las que se hace referencia en este tema está disponible para los usuarios con acceso a todo BMJ Best Practice.
Diferenciales
- Síncope
- Ataque isquêmico transitório (AIT)
- Distúrbios do sono
Más DiferencialesGuías de práctica clínica
- Epilepsies in children, young people and adults
- Teratogenesis, perinatal, and neurodevelopmental outcomes after in utero exposure to antiseizure medication
Más Guías de práctica clínicaFolletos para el paciente
Epilepsia: perguntas a fazer ao seu médico
Epilepsia: o que é?
Más Folletos para el pacienteInicie sesión o suscríbase para acceder a todo el BMJ Best Practice
El uso de este contenido está sujeto a nuestra cláusula de exención de responsabilidad